Your browser doesn't support javascript.

Portal de Búsqueda de la BVS Colombia

Información y Conocimiento para la Salud

Home > Búsqueda > ()
XML
Imprimir Exportar

Formato de exportación:

Exportar

Email
Adicionar mas contactos
| |

Drug prices in Latin American countries: the case of rheumatoid arthritis Biosimilars

Mosegui, Gabriela Bittencourt Gonzalez; Antõnanzas, Fernando; Vianna, Cid Manso de Mello; Rojas, Paula.
Adv Rheumatol ; 61: 14, 2021. tab
Artículo en Inglés | LILACS | ID: biblio-1152743
Abstract

Background:

The objective of this paper is to analyze the prices of biological drugs in the treatment of Rheumatoid Arthritis (RA) in three Latin American countries (Brazil, Colombia and Mexico), as well as in Spain and the United States of America (US), from the point of market entry of biosimilars.

Methods:

We analyzed products authorized for commercialization in the last 20 years, in Brazil, Colombia, and Mexico, comparing them to the United States of America (USA) and Spain. For this analysis, we sought the prices and registries of drugs marketed between 1999 and October 1, 2019, in the regulatory agencies' databases. The pricing between countries was based on purchasing power parity (PPP).

Results:

The US authorized the commercialization of 13 distinct biologicals and four biosimilars in the period. Spain and Brazil marketed 14 biopharmaceuticals for RA, ten original, four biosimilars. Colombia and Mexico have authorized three biosimilars in addition to the ten biological ones. For biological drug prices, the US is the most expensive country. Spain's price behavior seems intermediate when compared to the three LA countries. Brazil has the highest LA prices, followed by Mexico and Colombia, which has the lowest prices. Spain has the lowest values in PPP, compared to LA countries, while the US has the highest prices.

Conclusions:

The economic effort that LA countries make to access these medicines is much higher than the US and Spain. The use of the PPP ensured a better understanding of the actual access to these inputs in the countries analyzed.(AU)
Biblioteca responsable: BR1.1